SNGX - Soligenix reports positive HyBryte data in late-stage cutaneous T-cell lymphoma study

Soligenix (SNGX) announces key details of HyBryte (hypericin ointment 0.25%) in the the Phase 3 FLASH study in cutaneous T-cell lymphoma ((CTCL)) at the USCLC Annual Meeting, to be held on June 26, 2021. The Phase 3 FLASH trial enrolled a total of 169 patients (166 evaluable). The trial consisted of three treatment cycles.In the first treatment cycle, 116 patients received HyBryte treatment and 50 received placebo. A total of 16% of the patients receiving HyBryte achieved at least a 50% reduction in their lesions compared to only 4% in the placebo group at 8 weeks (p=0.04) during the first treatment cycle (primary endpoint). HyBryte was safe and well tolerated. Evaluation of 155 patients in Cycle 2 (110 receiving 12 weeks of HyBryte treatment and 45 receiving 6 weeks of placebo followed by 6 weeks of HyBryte), demonstrated that the response rate among the 12-week treatment group was 40% (p<0.0001 vs the

For further details see:

Soligenix reports positive HyBryte data in late-stage cutaneous T-cell lymphoma study